These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 26897759)

  • 1. [New therapeutic strategy for head-and-neck neoplasms--Molecular target therapy].
    Fujii M
    Nihon Jibiinkoka Gakkai Kaiho; 2015 Nov; 118(11):1369-74. PubMed ID: 26897759
    [No Abstract]   [Full Text] [Related]  

  • 2. Should cetuximab replace cisplatin in head and neck cancer?
    Rowan K
    J Natl Cancer Inst; 2010 Jan; 102(2):74-6, 78. PubMed ID: 20054019
    [No Abstract]   [Full Text] [Related]  

  • 3. [Chemoradiation for locally advanced head and neck cancers: Cetuximab or cisplatin?].
    Mazeron JJ
    Bull Cancer; 2016 Apr; 103(4):319. PubMed ID: 27055355
    [No Abstract]   [Full Text] [Related]  

  • 4. Is high-dose intensity intraarterial cisplatin chemoradiotherapy for head and neck carcinoma feasible?
    Robbins KT
    Cancer; 2005 Feb; 103(3):447-50. PubMed ID: 15633205
    [No Abstract]   [Full Text] [Related]  

  • 5. The chemoradiation paradigm in head and neck cancer.
    Seiwert TY; Salama JK; Vokes EE
    Nat Clin Pract Oncol; 2007 Mar; 4(3):156-71. PubMed ID: 17327856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review.
    Murdoch D
    Curr Opin Oncol; 2007 May; 19(3):216-21. PubMed ID: 17414639
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab in metastatic or recurrent head and neck cancer: the EXTREME trial.
    Rivera F; García-Castaño A; Vega N; Vega-Villegas ME; Gutiérrez-Sanz L
    Expert Rev Anticancer Ther; 2009 Oct; 9(10):1421-8. PubMed ID: 19828002
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting epidermal growth factor receptor in head and neck cancer: lessons learned from cetuximab.
    Moon C; Chae YK; Lee J
    Exp Biol Med (Maywood); 2010 Aug; 235(8):907-20. PubMed ID: 20562132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in head and neck cancer therapy: the role of new cytotoxic and molecular-targeted agents.
    Caponigro F; Milano A; Basile M; Ionna F; Iaffaioli RV
    Curr Opin Oncol; 2006 May; 18(3):247-52. PubMed ID: 16552236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Successes in late solid tumors. New therapy offer].
    Arnheim K
    MMW Fortschr Med; 2004 Nov; 146(47):71. PubMed ID: 15624667
    [No Abstract]   [Full Text] [Related]  

  • 12. Concurrent cetuximab, cisplatin, and concomitant boost radiotherapy for locoregionally advanced, squamous cell head and neck cancer: a pilot phase II study of a new combined-modality paradigm.
    Pfister DG; Su YB; Kraus DH; Wolden SL; Lis E; Aliff TB; Zahalsky AJ; Lake S; Needle MN; Shaha AR; Shah JP; Zelefsky MJ
    J Clin Oncol; 2006 Mar; 24(7):1072-8. PubMed ID: 16505426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum.
    Brizel DM; Esclamado R
    J Clin Oncol; 2006 Jun; 24(17):2612-7. PubMed ID: 16763273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical application of EGFR inhibitors in head and neck squamous cell cancer.
    Astsaturov I; Cohen RB; Harari PM
    Cancer Treat Res; 2008; 139():135-52. PubMed ID: 18236715
    [No Abstract]   [Full Text] [Related]  

  • 15. Radiation combined with EGFR signal inhibitors: head and neck cancer focus.
    Harari PM; Huang S
    Semin Radiat Oncol; 2006 Jan; 16(1):38-44. PubMed ID: 16378905
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Integrating novel agents into the curative treatment of head and neck cancer.
    Haddad R; Allen A; Wirth L; Tishler R; Posner M
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):157-9. PubMed ID: 16445367
    [No Abstract]   [Full Text] [Related]  

  • 17. Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1α and Notch1 in head neck squamous cell carcinoma.
    Wang WM; Zhao ZL; Ma SR; Yu GT; Liu B; Zhang L; Zhang WF; Kulkarni AB; Sun ZJ; Zhao YF
    PLoS One; 2015; 10(2):e0119723. PubMed ID: 25723392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concurrent cetuximab, cisplatin, and radiation for squamous cell carcinoma of the head and neck in vitro.
    Zhang N; Erjala K; Kulmala J; Qiu X; Sundvall M; Elenius K; Grénman R
    Radiother Oncol; 2009 Sep; 92(3):388-92. PubMed ID: 19447510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
    Jedlinski A; Ansell A; Johansson AC; Roberg K
    J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of advanced head and neck cancer.
    Yalçýn B; Büyükçelik A; Utkan G
    N Engl J Med; 2004 Aug; 351(8):829-31; author reply 829-31. PubMed ID: 15320314
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.